Design and Synthesis of Dual EZH2/BRD4 Inhibitors to Target Solid Tumors

Area of Science:

• Oncology
• Epigenetics
• Medicinal Chemistry

Background:

• EZH2 inhibitors targeting histone lysine 27 (H3K27) trimethylation are effective in hematological cancers but face resistance in solid tumors.
• In solid tumors, EZH2 inhibition leads to H3K27 acetylation, causing acquired drug resistance.
• Combining EZH2 and BRD4 inhibitors shows potential to resensitize solid cancer cells.

Purpose of the Study:

• To design, synthesize, and evaluate novel dual EZH2/BRD4 inhibitors.
• To identify a potent compound capable of overcoming EZH2 inhibitor resistance in solid tumors.
• To explore the therapeutic potential of dual EZH2/BRD4 inhibitors in preclinical cancer models.

Main Methods:

• Chemical synthesis of novel dual EZH2/BRD4 inhibitors.
• In vitro biological evaluation of inhibitory activity and antiproliferative effects against solid cancer cell lines.
• In vivo efficacy studies in lung and pancreatic cancer xenograft mouse models.

Main Results:

• A first-in-class dual EZH2/BRD4 inhibitor, YM458, was developed.
• YM458 demonstrated potent inhibition of both EZH2 and BRD4.
• YM458 exhibited significant antiproliferative activity against 11 solid cancer cell lines and showed therapeutic potential in vivo.

Conclusions:

• Dual EZH2/BRD4 inhibition represents a viable strategy to overcome resistance in solid tumors.
• YM458 is a promising candidate for treating EZH2 inhibitor-resistant solid cancers.
• This approach broadens the therapeutic scope for targeting resistant solid tumors.